RAPP
Rapport Therapeutics, Inc. Common Stock$38.32+3.10 (+8.82%)Prev Close$35.21·MCap$1.37B·P/E—·Vol185.2K·Yield—
▲
Buys (12M)
3
$1.61M
▼
Sells (12M)
31
$42.95M
◆
Net Activity
Net Seller
$41.34M
●
Active Insiders
8
last 12 mo
Over the past 12 months, insider activity at Rapport Therapeutics, Inc. Common Stock (RAPP) has been dominated by selling, with 3 insider purchases totaling $1.61M and 31 insider sales totaling $42.95M. The most recent insider transaction was by Third Rock Ventures V, L.P. (10 percent owner), who sold $743.8K worth of shares on May 28, 2026. Rapport Therapeutics, Inc. Common Stock operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $1.37B.
RAPP Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| May 28, 2026 | Third Rock Ventures V, L.P. | 10 percent owner | Sell | 18,572 | $40.05 | $743.8K | 6,280,525 |
| May 13, 2026 | Third Rock Ventures V, L.P. | 10 percent owner | Sell | 133,618 | $40.24 | $5.38M | 6,299,097 |
| May 11, 2026 | Third Rock Ventures V, L.P. | 10 percent owner | Sell | 276,513 | $40.12 | $11.09M0.8% OS | 6,437,733 |
| Apr 21, 2026 | Third Rock Ventures V, L.P. | 10 percent owner | Sell | 426,005 | $40.32 | $17.18M1.2% OS | 6,709,228 |
| Apr 21, 2026 | Yeleswaram Krishnaswamy | officer: Chief Development Officer | Sell | 20,225 | $39.99 | $808.8K | 246,426 |
| Apr 14, 2026 | Yeleswaram Krishnaswamy | officer: Chief Development Officer | Sell | 19,865 | $35.03 | $695.8K | 286,016 |
| Apr 9, 2026 | Yeleswaram Krishnaswamy | officer: Chief Development Officer | Sell | 360 | $34.90 | $12.6K | 286,516 |
| Mar 31, 2026 | Gault Cheryl | officer: Chief Operating Officer | Sell | 10,000 | $28.19 | $281.9K | 162,753 |
| Mar 26, 2026 | Yeleswaram Krishnaswamy | officer: Chief Development Officer | Sell | 10,115 | $29.99 | $303.4K | 286,876 |
| Mar 9, 2026 | Gault Cheryl | officer: Chief Operating Officer | Sell | 2,014 | $28.93 | $58.3K | 169,914 |
| Feb 19, 2026 | Bredt David | officer: Chief Scientific Officer | Sell | 8,500 | $29.02 | $246.7K | 394,675 |
| Feb 19, 2026 | Ceesay Abraham | director, officer: Chief Executive Officer | Sell | 10,916 | $29.35 | $320.4K | 558,528 |
| Feb 18, 2026 | Ceesay Abraham | Chief Executive Officer | Sell | 10,916 | $29.35 | $320.4K | 0 |
| Feb 17, 2026 | Bredt David | Chief Scientific Officer | Sell | 8,500 | $29.02 | $246.7K | 0 |
| Jan 22, 2026 | Ceesay Abraham | director, officer: Chief Executive Officer | Sell | 10,916 | $26.11 | $285.1K | 562,080 |
| Jan 16, 2026 | Bredt David | officer: Chief Scientific Officer | Sell | 8,500 | $26.84 | $228.1K | 395,775 |
| Jan 5, 2026 | Bredt David | officer: Chief Scientific Officer | Sell | 6,567 | $30.05 | $197.3K | 404,075 |
| Jan 5, 2026 | Yeleswaram Krishnaswamy | officer: Chief Development Officer | Sell | 2,840 | $30.05 | $85.3K | 296,991 |
| Dec 18, 2025 | Ceesay Abraham | Chief Executive Officer | Sell | 10,916 | $29.64 | $323.5K | 571,305 |
| Dec 16, 2025 | Bredt David | Chief Scientific Officer | Sell | 8,500 | $30.02 | $255.1K | 393,438 |
| Dec 1, 2025 | Gault Cheryl | Chief Operating Officer | Sell | 5,000 | $30.10 | $150.5K | 171,928 |
| Nov 18, 2025 | Bredt David | Chief Scientific Officer | Sell | 8,500 | $25.19 | $214.1K | 406,486 |
| Nov 18, 2025 | Ceesay Abraham | Chief Executive Officer | Sell | 10,916 | $25.20 | $275.0K | 576,802 |
| Oct 16, 2025 | Bredt David | Chief Scientific Officer | Sell | 8,500 | $25.79 | $219.2K | 410,724 |
| Oct 16, 2025 | Ceesay Abraham | Chief Executive Officer | Sell | 10,916 | $25.81 | $281.7K | 580,765 |
| Sep 19, 2025 | Ceesay Abraham | Chief Executive Officer | Sell | 76,420 | $26.32 | $2.01M | 586,812 |
| Sep 17, 2025 | Bredt David | Chief Scientific Officer | Sell | 8,500 | $24.19 | $205.6K | 421,544 |
| Sep 15, 2025 | Huber Reid M | Buy | 20,400 | $24.48 | $499.4K | 20,400 | |
| Sep 15, 2025 | PAUL STEVEN M | Buy | 41,666 | $24.65 | $1.03M | 41,666 | |
| Sep 11, 2025 | Young Wendy B. | Buy | 3,500 | $22.60 | $79.1K | 9,500+58% | |
| Sep 10, 2025 | Gault Cheryl | Chief Operating Officer | Sell | 5,000 | $38.33 | $191.7K | 171,928 |
| Aug 18, 2025 | Bredt David | Chief Scientific Officer | Sell | 8,500 | $15.00 | $127.5K | 426,842 |
| Jul 16, 2025 | Bredt David | Chief Scientific Officer | Sell | 8,500 | $14.00 | $119.0K | 435,142 |
| Jun 18, 2025 | Bredt David | Chief Scientific Officer | Sell | 8,500 | $11.00 | $93.5K | 443,642 |
| May 19, 2025 | Bredt David | Chief Scientific Officer | Sell | 8,500 | $9.56 | $81.3K | 452,142 |
| Apr 16, 2025 | Bredt David | Chief Scientific Officer | Sell | 8,500 | $9.57 | $81.3K | 460,642 |
| Mar 17, 2025 | Bredt David | Chief Scientific Officer | Sell | 8,500 | $10.85 | $92.2K | 469,142 |
| Mar 13, 2025 | Ignelzi Troy A. | Chief Financial Officer | Buy | 10,000 | $10.10 | $101.0K | 10,000 |
| Mar 13, 2025 | Young Wendy B. | Buy | 6,000 | $10.21 | $61.2K | 6,000 | |
| Jul 3, 2024 | HEALY JAMES | Director | Buy | 44,032 | $24.52 | $1.08M | 40,851 |
| Jun 10, 2024 | HEALY JAMES | Buy | 558,824 | $17.00 | $9.50M1.5% OS | 1,863,327+43% |
RAPP Insider Buying Activity
The following table shows recent insider purchases of Rapport Therapeutics, Inc. Common Stock (RAPP) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Sep 15, 2025 | Huber Reid M | Buy | 20,400 | $24.48 | $499.4K | 20,400 | |
| Sep 15, 2025 | PAUL STEVEN M | Buy | 41,666 | $24.65 | $1.03M | 41,666 | |
| Sep 11, 2025 | Young Wendy B. | Buy | 3,500 | $22.60 | $79.1K | 9,500+58% | |
| Mar 13, 2025 | Ignelzi Troy A. | Chief Financial Officer | Buy | 10,000 | $10.10 | $101.0K | 10,000 |
| Mar 13, 2025 | Young Wendy B. | Buy | 6,000 | $10.21 | $61.2K | 6,000 | |
| Jul 3, 2024 | HEALY JAMES | Director | Buy | 44,032 | $24.52 | $1.08M | 40,851 |
| Jun 10, 2024 | HEALY JAMES | Buy | 558,824 | $17.00 | $9.50M1.5% OS | 1,863,327+43% |
RAPP Insider Selling Activity
The following table shows recent insider sales of Rapport Therapeutics, Inc. Common Stock (RAPP) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| May 28, 2026 | Third Rock Ventures V, L.P. | 10 percent owner | Sell | 18,572 | $40.05 | $743.8K | 6,280,525 |
| May 13, 2026 | Third Rock Ventures V, L.P. | 10 percent owner | Sell | 133,618 | $40.24 | $5.38M | 6,299,097 |
| May 11, 2026 | Third Rock Ventures V, L.P. | 10 percent owner | Sell | 276,513 | $40.12 | $11.09M0.8% OS | 6,437,733 |
| Apr 21, 2026 | Third Rock Ventures V, L.P. | 10 percent owner | Sell | 426,005 | $40.32 | $17.18M1.2% OS | 6,709,228 |
| Apr 21, 2026 | Yeleswaram Krishnaswamy | officer: Chief Development Officer | Sell | 20,225 | $39.99 | $808.8K | 246,426 |
| Apr 14, 2026 | Yeleswaram Krishnaswamy | officer: Chief Development Officer | Sell | 19,865 | $35.03 | $695.8K | 286,016 |
| Apr 9, 2026 | Yeleswaram Krishnaswamy | officer: Chief Development Officer | Sell | 360 | $34.90 | $12.6K | 286,516 |
| Mar 31, 2026 | Gault Cheryl | officer: Chief Operating Officer | Sell | 10,000 | $28.19 | $281.9K | 162,753 |
| Mar 26, 2026 | Yeleswaram Krishnaswamy | officer: Chief Development Officer | Sell | 10,115 | $29.99 | $303.4K | 286,876 |
| Mar 9, 2026 | Gault Cheryl | officer: Chief Operating Officer | Sell | 2,014 | $28.93 | $58.3K | 169,914 |
| Feb 19, 2026 | Bredt David | officer: Chief Scientific Officer | Sell | 8,500 | $29.02 | $246.7K | 394,675 |
| Feb 19, 2026 | Ceesay Abraham | director, officer: Chief Executive Officer | Sell | 10,916 | $29.35 | $320.4K | 558,528 |
| Feb 18, 2026 | Ceesay Abraham | Chief Executive Officer | Sell | 10,916 | $29.35 | $320.4K | 0 |
| Feb 17, 2026 | Bredt David | Chief Scientific Officer | Sell | 8,500 | $29.02 | $246.7K | 0 |
| Jan 22, 2026 | Ceesay Abraham | director, officer: Chief Executive Officer | Sell | 10,916 | $26.11 | $285.1K | 562,080 |
| Jan 16, 2026 | Bredt David | officer: Chief Scientific Officer | Sell | 8,500 | $26.84 | $228.1K | 395,775 |
| Jan 5, 2026 | Bredt David | officer: Chief Scientific Officer | Sell | 6,567 | $30.05 | $197.3K | 404,075 |
| Jan 5, 2026 | Yeleswaram Krishnaswamy | officer: Chief Development Officer | Sell | 2,840 | $30.05 | $85.3K | 296,991 |
| Dec 18, 2025 | Ceesay Abraham | Chief Executive Officer | Sell | 10,916 | $29.64 | $323.5K | 571,305 |
| Dec 16, 2025 | Bredt David | Chief Scientific Officer | Sell | 8,500 | $30.02 | $255.1K | 393,438 |
| Dec 1, 2025 | Gault Cheryl | Chief Operating Officer | Sell | 5,000 | $30.10 | $150.5K | 171,928 |
| Nov 18, 2025 | Bredt David | Chief Scientific Officer | Sell | 8,500 | $25.19 | $214.1K | 406,486 |
| Nov 18, 2025 | Ceesay Abraham | Chief Executive Officer | Sell | 10,916 | $25.20 | $275.0K | 576,802 |
| Oct 16, 2025 | Bredt David | Chief Scientific Officer | Sell | 8,500 | $25.79 | $219.2K | 410,724 |
| Oct 16, 2025 | Ceesay Abraham | Chief Executive Officer | Sell | 10,916 | $25.81 | $281.7K | 580,765 |
| Sep 19, 2025 | Ceesay Abraham | Chief Executive Officer | Sell | 76,420 | $26.32 | $2.01M | 586,812 |
| Sep 17, 2025 | Bredt David | Chief Scientific Officer | Sell | 8,500 | $24.19 | $205.6K | 421,544 |
| Sep 10, 2025 | Gault Cheryl | Chief Operating Officer | Sell | 5,000 | $38.33 | $191.7K | 171,928 |
| Aug 18, 2025 | Bredt David | Chief Scientific Officer | Sell | 8,500 | $15.00 | $127.5K | 426,842 |
| Jul 16, 2025 | Bredt David | Chief Scientific Officer | Sell | 8,500 | $14.00 | $119.0K | 435,142 |
| Jun 18, 2025 | Bredt David | Chief Scientific Officer | Sell | 8,500 | $11.00 | $93.5K | 443,642 |
| May 19, 2025 | Bredt David | Chief Scientific Officer | Sell | 8,500 | $9.56 | $81.3K | 452,142 |
| Apr 16, 2025 | Bredt David | Chief Scientific Officer | Sell | 8,500 | $9.57 | $81.3K | 460,642 |
| Mar 17, 2025 | Bredt David | Chief Scientific Officer | Sell | 8,500 | $10.85 | $92.2K | 469,142 |
RAPP Insiders
Similar Stocks to RAPP
VRTX
Vertex Pharmaceuticals Incorporated
$445.21+0.04%
$113.41B
REGN
Regeneron Pharmaceuticals, Inc.
$614.20+0.45%
$65.47B
ALNY
Alnylam Pharmaceuticals, Inc.
$283.35-2.09%
$40.46B
RVMD
Revolution Medicines, Inc.
$153.65+2.96%
$31.73B
UTHR
United Therapeutics Corporation
$542.43-0.54%
$23.12B
INSM
Insmed Incorporated
$98.28+1.64%
$20.41B
INCY
Incyte Corporation
$108.85+0.95%
$20.11B
MRNA
Moderna, Inc.
$50.18+1.06%
$18.89B